Home / People / Jane Hollywood
Portrait ofJane Hollywood

Jane Hollywood

Patent Attorney

CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Jane is a European and UK patent attorney specialising in biotechnology.  She is recognised as a leading practitioner in her field by IAM Patent 1000 and Legal 500, who praise her technical understanding, skill at European Patent Office proceedings, and clear and strategic advice to clients.

With over 20 years of experience, Jane provides advice on all aspects of patent strategy. She is experienced in opposition and appeal proceedings before the European Patent Office, where she has represented clients across a range of life science technologies. Jane’s particular interest is in relation to genetic engineering or synthetic biology inventions in the healthcare and consumer sectors, including biologics, gene and cell therapies and food products.  

Jane co-manages CMS’s equIP Life Sciences programme, which supports early/growth stage life sciences business. She is also an Expert-In-Residence providing support to start-ups at the Imperial Enterprise Lab.

more less

"Jane Hollywood has a very good understanding of biotech science and significant expertise in EPO proceedings. She is very clear in explaining situations to clientele. She maintains good relationships, is available, responsive and provides strategic advice. She is a great sounding board for ideas and offers well-informed opinions."

IAM Patent 1000, 2023

"Jane Hollywood is very approachable, very invested, and goes the extra mile." Tier 1: PATMA Patent Attorney.

Legal 500, 2022

Also holding a PhD - ….. Hollywood “has a huge amount of technical expertise. She always explains everything extremely thoroughly and gives a good overview of all the key factors”.

IAM Patent 1000, 2021

“Biotech specialist Hollywood is also one to watch, thanks to the foothold she is carving in burgeoning fields such as plant sciences and the nascent cannabis industry.”

IAM Patent 1000, 2020


  • 2008 – European and UK Patent Attorney
  • 2003 – PhD, UCL, London
  • 2000 – BSc Biology, University of Bristol
more less


On the Pulse Webinar Series 2023 - Autumn
On the Pulse webinar series brings you updates on the latest legal and commercial developments in the life sciences & healthcare sector. The Autumn edition will see our CMS sector specialists cover: Commercial - Deal landscape and transaction trends in the Life Sciences SectorDispute Resolution - The midnight clause: why choice of law and jurisdiction clauses matterPublic Procurement - Typical pitfalls to be avoided in a procurement process for pharma and medical devices suppliesequIP - Pitfalls for life sciences start-ups to avoidEach webinar will be one hour in length with a 15-minute Q&A session.To register for the full series or just the topics of interest to you, click on the registration links below.To watch the Spring webinars in the On the Pulse series, visit here.
Cannabis law and legislation in the UK
Medical use It is in principle lawful to produce, supply, offer to supply, import, export, have in possession or cultivate (in the case of the plant) cannabis products, including medicinal products...
UK Re-joins Horizon Europe
On 7 September, the UK re-joined the world’s largest research collaboration programme, Horizon Europe. The decision has been welcomed by academics and life sciences businesses within the UK and the...
Is a patient in a clinical trial considered to be a member of the public...
In T 0670/20, the question was whether the internal structure of medicinal tablets had been made available to the public by patients taking part in clinical trials involving administration of the tablets...
What is the significance of a clinical trial protocol as prior art at the...
The EPO Appeal Board has further refined their view on when prior art disclosures of clinical trial protocols are an issue for patentability of medical use claims. Decision T1806/18 In decision T1806/18...
Armchair inventions part 2:  Preliminary opinion on plausibility at the...
The issue of plausibility was previously referred to the Enlarged Board of Appeal (EBA), the highest judicial authority at the European Patent Office (EPO). Our article on the referral can be found here...
Life Sciences are reaping the reward of digital advances but IP and contract...
Digital transformation in life sciences is creating opportunities to counter healthcare’s most intractable problems from treating rare diseases to accelerating diagnostics and reducing treatment backlogs.But technological advances are outstripping legislative and regulatory frameworks giving rise to a landscape strewn with issues over data, privacy and IP, the recent CMS Global Life Sciences & Healthcare Forum 2022 heard.“Tech­no­logy change obviously brings with it risks in implementation and new uses of technology and new regulation and legislation brings new risk,” Jeremy Mash, partner at CMS London, told delegates.AI is a potent force in life sciences with machine learning and patient data opening up new opportunities to revolutionise healthcare and relieve systems bogged down by laborious processes and shrinking budgets.The advances are welcomed across life sciences and digital has been enshrined in most nation’s health system planning but some fundamental principles such as who owns or is responsible for patient data, new routes to treatments and the consequences of mistakes have yet to be fully tested.“There are situations where you can see that evolving into risk and legal problems,” added Jeremy. “There is increasing use of legislation in the space and there is concern about where it is going to lead. There are a lot of data issues about quite what the ‘black box’ is doing and you can see people starting to raise concerns about how their data is being used.“There is also a lot talk about who is liable if that AI does not work. Is it the person who implemented it or the person designed it?”CMS examined the emerging issues in its Technology Transformation report, which surveyed 510 senior counsel and risk managers across sectors and discovered a range of preparedness and safeguards.It identified that IP issues represent 65% of expected future technology disputes, observed Jane Hollywood, partner at CMS London and patent attorney. She said the existing risk management systems for identifying, analysing, reviewing, mitigating and monitoring IP risk may need stiff­en­ing.“It's one thing to have contractual obligations and training for your people governing how you protect your IP and not misuse third party IP,” she told the Forum, in Brussels. “But it's quite another to ensure that your procedures remain adequate while you're operating in a world of machine learning algorithms and AI facilitated decision making.”She added: “The IP system does not evolve as quickly as technology advances and therefore we can have challenges obtaining protection for new technologies. We've seen this very much with AI and digital health technologies where patent protection can be difficult to get.”She said that identifying ownership and capturing developments in a fast-moving sector where collaboration and joint ventures are common can also generate disputes.“Big Pharma is increasingly partnering with digital health companies for drug discovery and patient engagement and clinical trial automation and, again, there's a lack of clarity about who owns the data that's generated from these partnerships so this is also likely to lead to disputes in the future,” said Jane.To read the full survey, visit Technology Transformation report.
Pork futures CMS partner Jane Hollywood talks to Dr Ruth Faram, a stem cell scientist who is the co-founder and chief scientific officer of HigherSteaks, a UK company aiming to develop non-farmed and sustainable meat products.
To modify or not to modify? Genetic Modification and Gene Editing – A divergence...
Against the backdrop of the cost-of-living crisis it is argued that the UK could bolster food security, combat climate change and lower food prices by relaxing the rules on and around genetic engineering...
Global LSHC Forum 2022
Uncertain times, an evolving legal framework: managing risks and ensuring social responsibility in the life sciences & healthcare sector
Global Life Sciences & Healthcare Forum 2022
Uncertain times, an evolving legal framework: managing risks and ensuring social responsibility in the life sciences & healthcare sector
What is a patent and what can I do with it?
Imagine, you have developed an AI led diagnostic tool which provides oncologists with a percentage score of how likely it is that a patient’s mole is cancerous. You want to commercialise it, but how do you stop others from copying your invention without your permission and competing against you? How broad is the protection offered and how long does it last? Should you share the details of your invention to potential investors (or other third parties) before you have obtained a granted patent? Is your invention even capable of being protected by a patent? Our expert patent team answer key questions that inventors in similar situations should consider before launching a new product.If you would like to discuss patents in more detail, please get in touch. To read the in­tro­duc­tion to patents paper download the pdf below.